AACR Conference Coverage

Trovagene Announces Update to Phase 1b/2 AML Trial Data Presented at AACR - Additional Patients Achieve Complete Response at Two Highest Dose Levels of Onvansertib

(Markets Insider) Apr 5, 2019 - Trovagene, Inc. today announced updated data following its presentation at the American Association for Cancer Research.

read article

People Living With Incurable Cancers Urge More Research

(ABC News/Associated Press) Apr 3, 2019 - Millions of people are surviving for years with cancers that have spread widely and are considered incurable, and there's a new push for more research on what it's like to live with the disease, not just how to treat it. Tom Smith hesitated to buy light bulbs guaranteed for up to 10 years, thinking they'd outlast him. Terry Langbaum debated filling a prescription for a $13,000-a-month drug that keeps cancer from worsening for three months on average and carries six pages of warnings. “There are so many of us living with cancers that can’t be cured,” Langbaum said. “We study the treatments but we don’t study what it’s like to be the person going through treatment.”

read article

Epigenetic Therapies May Prime Tumors to Better Respond to Other Treatments, AACR Speakers Say

(GenomeWeb) Apr 4, 2019 - Epigenetic therapies may help push solid tumors to be more responsive to other forms of treatment, according to speakers at this year's American Association for Cancer Research meeting here.

read article (free registration required)

Johns Hopkins Faculty, Staff Members Address Travails of Navigating Metastatic Cancer Survivorship in New England Journal of Medicine Perspective Piece

(Johns Hopkins Medicine) Apr 3, 2019 - Due to advances in treatment, an ever-increasing number of patients are living longer as metastatic cancer survivors. They and their doctors face a host of new challenges that require immediate attention. It used to be when you were diagnosed with metastatic cancer, you were told to get your affairs in order, period. Now, with advances in research and treatment, a diagnosis of metastatic disease is no longer an immediate death sentence. Many of these patients, who once would have died within months, are now living extended years. But it’s not as simple as it sounds. Two Johns Hopkins Kimmel Cancer Center professionals know this all too well.

read press release

Bristol-Myers Squibb Announces Long-Term Survival Results from Pooled Analyses of Opdivo (nivolumab) in Previously-Treated Non-Small Cell Lung Cancer Patients

(BMS) Apr 2, 2019 - Bristol-Myers Squibb Company today announced results from pooled analyses of survival data from four studies (CheckMate -017, -057, -063 and -003; n=664) in patients with previously-treated advanced non-small cell lung cancer (NSCLC) who were treated with Opdivo (nivolumab). In the pooled analysis of the four studies, 14% of all Opdivo-treated patients were alive at four years. Notably, in patients with PD-L1 ≥1% and <1%, four-year overall survival (OS) rates were 19% and 11%, respectively. In the pooled analysis of the two phase 3 trials, CheckMate -017 and -057, the four-year OS rate for Opdivo-treated patients was 14% compared to 5% for docetaxel-treated patients. Additionally, exploratory landmark analysis of OS found that of patients who had a complete or partial response at six months, 58% of those treated with Opdivo were alive four years later vs. 12% of patients treated with docetaxel.

read corporate press release

Pazdur Grills PD-1/PD-L1 Companies Over Lack Of Collaboration, Trial Redundancies

(BioCentury) Apr 1, 2019 - FDA's Oncology Center of Excellence Director Richard Pazdur pressed representatives from companies with marketed PD-1/PD-L1 inhibitors to explain why they aren't collaborating more in the clinic while questioning whether there are too many of these drugs on the market. His comments came as he moderated a session at the American Association for Cancer Research (AACR) meeting on Monday titled "PD-1 Pandemonium."

read article

AACR 2019 Roundup: Notes from a Weekend of Early Stage Cancer Results

(Xconomy National) Apr 3, 2019 - The American Association for Cancer Research’s annual meeting is wrapping up in Atlanta today. The conference typically focuses on early research and clinical work, not the big trials that can change the way doctors practice medicine and that compete for headline space at conferences like the American Society for Clinical Oncology. But AACR has its fair share of notable news, events, and reports. In case you missed the flow of stories that started last weekend—or you just want to refresh your memory—we’ve rounded up some of the highlights here and put them in the context you need to know if you’re not an expert.

read article

Despite Research Boom, Few Immunotherapy Studies Targeting Pancreatic Cancer

(BioPharma Dive) Apr 1, 2019 - Among the more than 2,600 clinical trials testing the most successful type of cancer immunotherapy, only 89, or about 3%, target pancreatic cancer, according to a new analysis unveiled Sunday by the nonprofit Cancer Research Institute. Pancreatic cancer remains one of the toughest tumor types to treat, and currently ranks as the third leading cause of cancer-related death in the U.S. — making the relative dearth of immunotherapy trials studying new treatment approaches notable.

read article

Using Blood, Saliva, Urine To Detect Cancer: Scientists' 'Holy Grail'

(CNN) Apr 3, 2019 - Testing for cancer in blood, urine or even saliva: That approach has been called the "holy grail" for diagnosing the second leading cause of death in the world, and it has been fueling an area of research that continues to raise eyebrows and questions.

read article

Combination of Virotherapy and Radiotherapy Safe, Shows Early Promise in Vulnerable Patients With Esophageal Cancer

(AACR 2019) Apr 2, 2019 - The experimental oncolytic adenovirus telomelysin (OBP-301) in combination with radiotherapy was safe and showed early clinical efficacy in vulnerable patients with esophageal cancer, according to results from a phase I clinical trial presented at the AACR Annual Meeting 2019, March 29–April 3.

read press release

Is Your Melanoma Hot Enough For Immunotherapy?

(UCCC/Colorado Cancer Blogs) Apr 2, 2019 - Melanomas tend to be “hot” or “cold” – if they’re hot, immunotherapy lights melanoma tumors like beacons for elimination by the immune system; but 40-50 percent of melanomas are cold, making them invisible to the immune system, and patients with cold tumors tend to show little benefit from immunotherapies.

read article

Breast Cancer: Estrogen Byproducts May Predict Outlook

(Medical News Today) Apr 2, 2019 - New research finds a link between the ratio of two types of estrogen metabolites and the risk of mortality from any cause among women who receive a diagnosis of breast cancer.

read article

BriaCell's Lead Candidate Combined With KEYTRUDA®: Strong Evidence of Rapid Additive or Synergistic Anti-Tumor Activity

(Morningstar) Apr 3, 2019 - As presented at the American Association for Cancer Research (AACR) annual meeting: early efficacy data for the first six advanced breast cancer patients dosed with Bria-IMT™ in combination with KEYTRUDA® suggest additive or synergistic effects on tumor regression (“shrinkage”).

read article

Dynavax Presents Phase 1b Data on Inhaled DV281 TLR9 Agonist at the 2019 AACR Annual Meeting

(Markets Insider) Apr 2, 2019 - Using an investigational safety treatment regimen, inhaled DV281 in combination with systemic nivolumab was well tolerated in a population of heavily pre-treated NSCLC patients.

read article

OSE Immunotherapeutics Presents New Clinical and Preclinical Data on its Immuno-Oncology Portfolio at AACR 2019

(Associated Press) Apr 2, 2019 - Oral presentation highlights investigator case reports showing early signs of activity of Tedopi® in patients with non-small cell lung cancer in third-line treatment after checkpoint inhibitor failure.

read article

Iovance Biotherapeutics Presents Data at AACR Annual Meeting on T-Cell Diversity and Persistence in Patients Receiving Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel

(Iovance Biotherapeutics) Apr 1, 2019 - Data from cohort 2 of the innovaTIL-01 study support polyclonal approach necessary to treat metastatic melanoma.

read corporate press release

New Glioblastoma Vaccine Shows Promising Results in Phase 1b Clinical Trial

(Markets Insider) Apr 3, 2019 - Glioblastoma is the most aggressive type of primary brain cancer, one with a prognosis of 11-15 months with standard treatment.

read article

Inovio's Novel HPV Therapy INO-3106 Demonstrates Clinical Efficacy Against Rare Respiratory Tract Tumors in Pilot Clinical Study

(Inovio) Apr 3, 2019 - Inovio Pharmaceuticals, Inc. today announced its novel therapy INO-3106 against the human papilloma virus type 6 (HPV 6) demonstrated clinical efficacy in a study of two patients with recurrent respiratory papillomatosis (RRP).

read corporate press release

Positive New Data on Imugene’s HER-Vaxx Cancer Vaccine Phase Ib Trial Presented at the American Association for Cancer Research 2019 Annual Meeting

(BioSpace) Apr 2, 2019 - Imugene Limited today presented new data on the Phase 1b study of its HER-Vaxx cancer vaccine at the American Association for Cancer Research (AACR) 2019 Annual Meeting in Atlanta, Georgia, USA.

read article

Rain Therapeutics Presents Preclinical Data on Lead Candidate Tarloxotinib at the American Association for Cancer Research (AACR) Annual Meeting

(Rain Therapeutics) Apr 3, 2019 - Rain Therapeutics Inc. today announced new preclinical data on tarloxotinib (Tarlox) presented at AACR 2019.

read corporate press release
Next Page